Related Experiment Video

Updated: Jun 13, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

Anti-hypertensive drugs and left ventricular hypertrophy: a clinical update

Alberto Milan1, Mimma A Caserta, Eleonora Avenatti

  • 1Hypertension Unit, Department of Medicine and Experimental Oncology, University of Torino, Via Genova, 3, Turin, Italy. alberto.milan@unito.it

Internal and Emergency Medicine
|May 19, 2010
PubMed

Insights

Left ventricular hypertrophy (LVH) in hypertensive patients increases cardiovascular risk. Renin-angiotensin-aldosterone system (RAAS) antagonists offer benefits beyond blood pressure control, including reducing fibrosis and mortality.

Area of Science:

  • Cardiology
  • Hypertension Research
  • Pharmacology

Background:

  • Left ventricular hypertrophy (LVH) is a cardiac structural remodeling resulting from systemic hypertension.
  • LVH is linked to increased cardiovascular morbidity and mortality.
  • Effective management of LVH is crucial in hypertensive patients.

Purpose of the Study:

  • To review the role of antihypertensive drugs in managing LVH.
  • To highlight the specific benefits of renin-angiotensin-aldosterone system (RAAS) antagonists in LVH.
  • To emphasize the importance of considering neuro-hormonal systems in LVH treatment.

Main Methods:

  • Literature review of antihypertensive therapies and their effects on LVH.
  • Analysis of studies focusing on myocardial interstitial fibrosis.
  • Evaluation of the impact of different drug classes on cardiovascular outcomes.

Main Results:

  • All classes of antihypertensive drugs show benefits for LVH.
  • RAAS antagonists provide additional benefits in inhibiting and reversing myocardial interstitial fibrosis.
  • Neuro-hormonal systems, including the sympathetic nervous system, play a significant role in hypertension and LVH.

Conclusions:

  • RAAS antagonists are recommended for hypertensive patients with LVH to prevent organ damage and reduce cardiovascular mortality/morbidity.
  • Comprehensive management considering multiple neuro-hormonal systems is essential for LVH.
  • Targeting RAAS offers specific advantages in mitigating cardiac fibrosis associated with hypertension.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...